GigaGen, Inc. clinical trials
Acquired by Grifols, Mar 9, 2021 · source ↗
The registry lists 3 studies whose lead sponsor is GigaGen, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Before and after it joined Grifols
- First submitted before GigaGen, Inc. became part of Grifols
- 0
- First submitted after GigaGen, Inc. became part of Grifols
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Phase
- Phase 1
- 3
Registry sponsor names on this page
- GigaGen, Inc.3 studies
Something wrong with this grouping? Tell us on the Grifols page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Grifols studies →
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus InfectionRecruitingNCT07024641Phase 1
Sponsor listed in the registry: GigaGen, Inc. · First submitted after GigaGen, Inc. became part of Grifols
- A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT06258304Phase 1
Sponsor listed in the registry: GigaGen, Inc. · First submitted after GigaGen, Inc. became part of Grifols
- Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 PatientsTerminatedNCT04883138Phase 1
Sponsor listed in the registry: GigaGen, Inc. · First submitted after GigaGen, Inc. became part of Grifols